Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America

Gustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, Bruno Guy, Laurent Chambonneau, Fernando Noriega, Nicholas Jackson, CYD-TDV Vaccine Trial Group, José Luis Arredondo-García, Alain Bouckenooghe, Maria Rosario Capeding, Tawee Chotpitayasunondh, Mary Noreen Chua, Margarita Cortés Supelano, Carmen Deseda, Reynaldo Dietze, Carina Frago, Sri Rezeki S Hadinegoro, Chan Quang Luong, Hussain Imam Hj Muhammad Ismail, Revathy Nallusamy, Punnee Pitisuttithum, Humberto Reynales, Doris Maribel Rivera-Medina, Kusnandi Rusmil, Usa Thisyakorn, Ngoc Huu Tran, T Anh Wartel, Dewa Nyoman Wirawan, In-Kyu Yoon, Betzana Zambrano, Gustavo Olivera-Botello, Laurent Coudeville, Karen Fanouillere, Bruno Guy, Laurent Chambonneau, Fernando Noriega, Nicholas Jackson, CYD-TDV Vaccine Trial Group, José Luis Arredondo-García, Alain Bouckenooghe, Maria Rosario Capeding, Tawee Chotpitayasunondh, Mary Noreen Chua, Margarita Cortés Supelano, Carmen Deseda, Reynaldo Dietze, Carina Frago, Sri Rezeki S Hadinegoro, Chan Quang Luong, Hussain Imam Hj Muhammad Ismail, Revathy Nallusamy, Punnee Pitisuttithum, Humberto Reynales, Doris Maribel Rivera-Medina, Kusnandi Rusmil, Usa Thisyakorn, Ngoc Huu Tran, T Anh Wartel, Dewa Nyoman Wirawan, In-Kyu Yoon, Betzana Zambrano

Abstract

Background: Asymptomatic dengue virus-infected individuals are thought to play a major role in dengue virus transmission. The efficacy of the recently approved quadrivalent CYD-TDV dengue vaccine against asymptomatic dengue virus infection has not been previously assessed.

Methods: We pooled data for 3 736 individuals who received either CYD-TDV or placebo at 0, 6, and 12 months in the immunogenicity subsets of 2 phase 3 trials (clinical trials registration NCT01373281 and NCT01374516). We defined a seroconversion algorithm (ie, a ≥4-fold increase in the neutralizing antibody titer and a titer of ≥40 from month 13 to month 25) as a surrogate marker of asymptomatic infection in the vaccine and placebo groups.

Results: The algorithm detected seroconversion in 94% of individuals with a diagnosis of virologically confirmed dengue between months 13 and 25, validating its discriminatory power. Among those without virologically confirmed dengue (n = 3 669), 219 of 2 485 in the vaccine group and 157 of 1 184 in the placebo group seroconverted between months 13 and 25, giving a vaccine efficacy of 33.5% (95% confidence interval [CI], 17.9%-46.1%) against asymptomatic infection. Vaccine efficacy was marginally higher in subjects aged 9-16 years (38.6%; 95% CI, 22.1%-51.5%). The annual incidence of asymptomatic dengue virus infection in this age group was 14.8%, which was 4.4 times higher than the incidence for symptomatic dengue (3.4%).

Conclusions: The observed vaccine efficacy against asymptomatic dengue virus infections is expected to translate into reduced dengue virus transmission if sufficient individuals are vaccinated in dengue-endemic areas.

Keywords: Asia; Latin America; adolescents; asymptomatic dengue virus infection; children; dengue vaccine; symptomatic dengue virus infection.

© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Disposition of participants in the analysis.
Figure 2.
Figure 2.
Distribution of dengue virus (DENV) antibody titer fold increases in individuals without virologically confirmed dengue between months 13 and 25. Only individuals with increased antibody titers between months 13 and 25 for at least 1 serotype were included for this analysis (vaccine group, n = 1583; placebo group, n = 708). For participants with increased antibody titers against >1 serotype, only the highest antibody titer ratio (titer a month 25/titer at month 13) was included.
Figure 3.
Figure 3.
Summary of algorithm sensitivity analyses for assessing vaccine efficacy against asymptomatic dengue virus (DENV) infection. The definition of seroconversion was varied from 3-fold to 9-fold increases in DENV antibody titer, with a constant minimum titer of 40 at month 25, to assess the impact on the attack rate and vaccine efficacy.

References

    1. Guzman MG, Harris E. Dengue. Lancet 2015; 385:453–65.
    1. Capeding MR, Tran NH, Hadinegoro SR et al. . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014; 384:1358–65.
    1. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR et al. . Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015; 373:1195–206.
    1. Villar L, Dayan GH, Arredondo-Garcia JL et al. . Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015; 372:113–23.
    1. Bhatt S, Gething PW, Brady OJ et al. . The global distribution and burden of dengue. Nature 2013; 496:504–7.
    1. Anders KL, Nga le H, Thuy NT et al. . Households as foci for dengue transmission in highly urban Vietnam. PLoS Negl Trop Dis 2015; 9:e0003528.
    1. Dussart P, Baril L, Petit L et al. . Clinical and virological study of dengue cases and the members of their households: the multinational DENFRAME Project. PLoS Negl Trop Dis 2012; 6:e1482.
    1. Yoon IK, Srikiatkhachorn A, Hermann L et al. . Characteristics of mild dengue virus infection in Thai children. Am J Trop Med Hyg 2013; 89:1081–7.
    1. Duong V, Lambrechts L, Paul RE et al. . Asymptomatic humans transmit dengue virus to mosquitoes. Proc Natl Acad Sci 2015; 112:14688–93.
    1. Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis 2011; 52:911–6.
    1. Kim TH, Johnstone J, Loeb M. Vaccine herd effect. Scand J Infect Dis 2011; 43:683–9.
    1. Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis 2012; 25:243–9.
    1. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009; 16:382–6.
    1. Kaplan EH, Wein LM. Smallpox eradication in West and Central Africa: surveillance-containment or herd immunity? Epidemiology 2003; 14:90–2.
    1. Kwong JC, Pereira JA, Quach S et al. . Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) cluster randomized trial: Pilot results from a household surveillance study to assess direct and indirect protection from influenza vaccination. Vaccine 2015; 33:4910–5.
    1. Lapinleimu K, Stenvik M. Experiences with polio vaccination and herd immunity in Finland. Dev Biol Stand 1981; 47:241–6.
    1. Lee MS, Lee LL, Chen HY, Wu YC, Horng CB. Post mass-immunization measles outbreak in Taoyuan County, Taiwan: dynamics of transmission, vaccine effectiveness, and herd immunity. Int J Infect Dis 1998; 3:64–9.
    1. Myint TT, Madhava H, Balmer P et al. . The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013; 30:127–51.
    1. Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V. Perspective: a five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vaccination strategies in Scandinavia. J Infect Dis 1999; 179:223–9.
    1. Piedra PA, Gaglani MJ, Kozinetz CA et al. . Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007; 120:e553–64.
    1. Plans P. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 2013; 32:961–6.
    1. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344:889–96.
    1. Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005; 294:202–10.
    1. Balmaseda A, Standish K, Mercado JC et al. . Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis 2010; 201:5–14.
    1. Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM. Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort. J Infect Dis 2015; 211:590–9.
    1. Endy TP, Anderson KB, Nisalak A et al. . Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011; 5:e975.
    1. Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172–80.
    1. Gordon A, Kuan G, Mercado JC et al. . The Nicaraguan pediatric dengue cohort study: incidence of inapparent and symptomatic dengue virus infections, 2004–2010. PLoS Negl Trop Dis 2013; 7:e2462.
    1. Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW. Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development. Am J Trop Med Hyg 2013; 88:962–70.
    1. Flipse J, Smit JM. The complexity of a dengue vaccine: a review of the human antibody response. PLoS Negl Trop Dis 2015; 9:e0003749.
    1. Salje H, Rodriguez-Barraquer I, Rainwater-Lovett K et al. . Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development. PLoS Negl Trop Dis 2014; 8:e2952.
    1. Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PloS One 2009; 4:e4991.
    1. de Alwis R, Beltramello M, Messer WB et al. . In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 2011; 5:e1188.
    1. Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA 2016; 113:728–33.
    1. Lai CY, Williams KL, Wu YC et al. . Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 2013; 7:e2451.
    1. Matheus S, Pham TB, Labeau B et al. . Kinetics of dengue non-structural protein 1 antigen and IgM and IgA antibodies in capillary blood samples from confirmed dengue patients. Am J Trop Med Hyg 2014; 90:438–43.
    1. Tsai WY, Lai CY, Wu YC et al. . High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 2013; 87:12562–75.
    1. Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat Rev Microbiol 2016; 14:45–54.
    1. Martinez-Vega RA, Danis-Lozano R, Diaz-Quijano FA et al. . Peridomestic infection as a determining factor of dengue transmission. PLoS Negl Trop Dis 2015; 9:e0004296.
    1. Vikram K, Nagpal BN, Pande V et al. . An epidemiological study of dengue in Delhi, India. Acta Trop 2016; 153:21–7.
    1. Villar LA, Rojas DP, Besada-Lombana S, Sarti E. Epidemiological trends of dengue disease in Colombia (2000–2011): a systematic review. PLoS Negl Trop Dis 2015; 9:e0003499.
    1. Endy TP, Chunsuttiwat S, Nisalak A et al. . Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 2002; 156:40–51.
    1. Montoya M, Gresh L, Mercado JC et al. . Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7:e2357.
    1. Busch MP, Sabino EC, Brambilla D et al. . Duration of dengue viremia in blood donors and relationships between donor viremia, unfection incidence and clinical case reports during a large epidemic. J Infect Dis 2016; 214:49–54.
    1. Porter KR, Beckett CG, Kosasih H et al. . Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop Med Hyg 2005; 72:60–6.
    1. Mammen MP, Pimgate C, Koenraadt CJ et al. . Spatial and temporal clustering of dengue virus transmission in Thai villages. PLoS Med 2008; 5:e205.
    1. Guy B, Nougarede N, Begue S et al. . Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008; 26:5712–21.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel